9 Meters Biopharma Inc

NASDAQ:NMTR   3:54:52 PM EDT
0.27
+0.01 (+2.24%)
Earnings Announcements

9 Meters Biopharma Announces Preliminary Results From Phase 2 Study Of Vurolenatide In Short Bowel Syndrome

Published: 06/30/2022 11:19 GMT
9 Meters Biopharma Inc (NMTR) - 9 Meters Biopharma Inc - Announces Positive Preliminary Results From Phase 2 Study of Vurolenatide in Short Bowel Syndrome.
9 Meters Biopharma Inc - Vurolenatide Was Generally Well Tolerated With No Adverse Events Leading to Early Study Withdrawal.
9 Meters Biopharma - End-of-phase 2 Meeting With FDA Scheduled for Mid-third Quarter.
9 Meters Biopharma - No Adverse Events Leading to Early Study Withdrawal.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.04

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.04

More details on our Analysts Page.